2. Search Result
Search Result
Results for "

AMPA Antagonist

" in MedChemExpress (MCE) Product Catalog:

56

Inhibitors & Agonists

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-12506A
    Naspm trihydrochloride
    5+ Cited Publications

    1-Naphthylacetyl spermine trihydrochloride

    		 iGluR Neurological Disease
    Naspm trihydrochloride (1-Naphthylacetyl spermine trihydrochloride), a synthetic analogue of Joro spider toxin, is a calcium permeable AMPA (CP-AMPA) receptors antagonist.
    Naspm trihydrochloride
  • HY-12506
    Naspm
    5+ Cited Publications

    1-Naphthylacetyl spermine

    		 iGluR Neurological Disease
    Naspm (1-Naphthyl acetyl spermine), a synthetic analogue of Joro spider toxin, is a calcium permeable AMPA (CP-AMPA) receptors antagonist.
    Naspm
  • HY-129030
    BDZ-g

    		iGluR Neurological Disease
    BDZ-g is a potent, selective antagonist of AMPA receptor. BDZ-g has the potential for the research of various neurological disorders involving excessive activity of AMPA receptors .
    BDZ-g
  • HY-136905
    AMPA receptor antagonist-2

    		iGluR Others
    AMPA receptor antagonist-2 (example 23) is an AMPA receptor antagonist .
    AMPA receptor antagonist-2
  • HY-145959
    AMPA receptor antagonist-3

    		iGluR Neurological Disease
    AMPA receptor antagonist-3 is an AMPA receptor antagonist extracted from patent US20070027143A1. AMPA receptor antagonist-3 can be used for the research of central nervous system disorders .
    AMPA receptor antagonist-3
  • HY-100785A
    gamma-DGG acetate

    γDGG acetate; γ-D-Glutamylglycine acetate

    		 iGluR Neurological Disease
    gamma-DGG acetate (γDGG acetate) is a competitive AMPA receptor blocker. gamma-DGG acetate is also a reversible Excitatory post-synaptic potentials (e.p.s.p.s) antagonist .
    gamma-DGG acetate
  • HY-W922811
    DL-Willardiine

    		Others Neurological Disease
    DL-Willardiine is an AMPA antagonist with an IC50 of 2 μM. DL-Willardiine can be utilized in psychotropic cccccc research .
    DL-Willardiine
  • HY-15070
    YM 900

    		iGluR Neurological Disease
    YM 900 is an AMPA receptor antagonist .
    YM 900
  • HY-15073
    Becampanel

    AMP 397

    		 iGluR Neurological Disease
    Becampanel (AMP397) is the first competitive AMPA antagonist and an antiepileptic agent.
    Becampanel
  • HY-107519
    (R)-3,4-DCPG

    		iGluR Neurological Disease
    (R)-3,4-DCPG is an AMPA and NMDA antagonist with a Kd of 77 μM for AMPA. (R)-3,4-DCPG complete antagonizes the NMDA-induced depolarization at a concentration of 500 μM. (R)-3,4-DCPG exhibits a weak antagonistic effect on kainate-induced depolarizations .
    (R)-3,4-DCPG
  • HY-108707
    LY3130481
    1 Publications Verification

    		 iGluR Neurological Disease
    LY3130481 is an orally available AMPA receptor antagonist, selectively inhibiting the IC50 value of AMPA/TARP γ-8 at 65 nM. LY3130481 has anticonvulsant, antiepileptic, and pain-relieving effects .
    LY3130481
  • HY-106039
    LY 215490

    		Others Neurological Disease
    LY 215490 is a selective, competitive AMPA receptor antagonist against AMPA, CGSl9755 and kainate with IC50 values of 4.8, 26.4 and 247 μM, respectively. LY 215490 shows neuroprotective effects in focal ischaemia .
    LY 215490
  • HY-15068
    NBQX
    Maximum Cited Publications
    10 Publications Verification

    FG9202

    		 iGluR Neurological Disease
    NBQX (FG9202) is a highly selective and competitive AMPA receptor antagonist. NBQX has neuroprotective and anticonvulsant activity .
    NBQX
  • HY-19433A
    (S)-ATPO

    		iGluR Neurological Disease
    (S)-ATPO is the (S)-enantiomer of ATPO, which is a competitive antagonist at GluR1-4 (AMPA-preferring) receptors .
    (S)-ATPO
  • HY-118814
    YM928

    		Others Neurological Disease
    YM928 is an orally active and noncompetitive α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist. YM928 inhibits AMPA receptor-mediated toxicity in primary rat hippocampal cultures with an IC50 value of 2 μM. YM928 blocks AMPA-induced intracellular calcium influx with an IC50 value of 3 μM and antagonizes AMPA-induced inward currents with an IC50 value of 1 μM. YM928 is promising for research of neurological disorders .
    YM928
  • HY-107603
    NS3763

    		iGluR Neurological Disease
    NS3763 is a selective and noncompetitive GLUK5 receptor antagonist with an IC50 of 1.6 µM. NS3763 does not show significant antagonistic properties on GLUK6, AMPA or NMDA receptors .
    NS3763
  • HY-15068A
    NBQX disodium
    Maximum Cited Publications
    10 Publications Verification

    FG9202 disodium

    		 iGluR Neurological Disease
    NBQX disodium (FG9202 disodium) is a highly selective and competitive AMPA receptor antagonist. NBQX disodium has neuroprotective and anticonvulsant activity .
    NBQX disodium
  • HY-18663B
    CP-465022 hydrochloride

    		iGluR Neurological Disease
    CP-465022 hydrochloride is a potent, and selective noncompetitive AMPA receptor antagonist with anticonvulsant activity. CP-465022 is against Kainate-induced response with an IC50 of 25 nM in rat cortical neurons. CP-465022 provides a new tool to investigate the role of AMPA receptors in physiological and pathophysiological processes .
    CP-465022 hydrochloride
  • HY-18663A
    CP-465022 maleate

    		iGluR Neurological Disease
    CP-465022 Maleate is a potent, and selective noncompetitive AMPA receptor antagonist with anticonvulsant activity. CP-465022 is against Kainate-induced response with an IC50 of 25 nM in rat cortical neurons. CP-465022 provides a new tool to investigate the role of AMPA receptors in physiological and pathophysiological processes .
    CP-465022 maleate
  • HY-18663
    CP-465022

    		iGluR Neurological Disease
    CP-465022 is a potent, and selective noncompetitive AMPA receptor antagonist with anticonvulsant activity. CP-465022 is against Kainate-induced response with an IC50 of 25 nM in rat cortical neurons. CP-465022 provides a new tool to investigate the role of AMPA receptors in physiological and pathophysiological processes .
    CP-465022
  • HY-103228
    GYKI 53655 hydrochloride

    LY300168 hydrochloride

    		 iGluR Neurological Disease
    GYKI 53655 (LY300168) hydrochloride is an α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) antagonist.
    GYKI 53655 hydrochloride
  • HY-117176
    KRP-199

    		iGluR Neurological Disease
    KRP-199 (compound 14h) is an α-amino-3-hydroxy-5-methylisoxazolepropionic acid receptor (AMPA-R) antagonist (Ki=16 nM) with high potency and selectivity for AMPA-R in vitro and good neuroprotective effects in vivo. KRP-199 can be used in the study of neurodegenerative diseases .
    KRP-199
  • HY-107518
    (R,S)-3,4-Dicarboxyphenylglycine

    (R,S)-3,4-DCPG

    		 iGluR Neurological Disease
    (R,S)-3,4-Dicarboxyphenylglycine ((RS)-3,4-DCPG) is an AMPA receptor antagonist. (R,S)-3,4-Dicarboxyphenylglycine antagonizes AMPA-mediated depolarization of motor neurons in neonatal rats. (R,S)-3,4-Dicarboxyphenylglycine can be used in the study of neurological diseases .
    (R,S)-3,4-Dicarboxyphenylglycine
  • HY-15066
    CNQX
    Maximum Cited Publications
    10 Publications Verification

    FG9065

    		 iGluR Neurological Disease
    CNQX (FG9065) is a potent and competitive AMPA/kainate receptor antagonist with IC50s of 0.3 μM and 1.5 μM, respectively. CNQX is a competitive non-NMDA receptor antagonist . CNQX blocks the expression of fear-potentiated startle in rats .
    CNQX
  • HY-15072
    Zonampanel

    YM 872

    		 iGluR Metabolic Disease
    Zonampanel (YM 872) is a selective antagonist of the glutamate receptor subtype, α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor.
    Zonampanel
  • HY-15069
    Fanapanel

    ZK200775; MPQX

    		 iGluR Neurological Disease
    Fanapanel (ZK200775) is a highly selective AMPA/kainate antagonist with little activity against NMDA; have Ki values of 3.2 nM, 100 nM, and 8.5 μM against quisqualate, kainate, and NMDA, respectively.
    Fanapanel
  • HY-15069A
    Fanapanel hydrate

    ZK200775 hydrate; MPQX hydrate

    		 iGluR Neurological Disease
    Fanapanel hydrate (ZK200775 hydrate) is a highly selective AMPA/kainate antagonist with little activity against NMDA; have Ki values of 3.2 nM, 100 nM, and 8.5 μM against quisqualate, kainate, and NMDA, respectively.
    Fanapanel hydrate
  • HY-18689
    SYM2206

    		iGluR Neurological Disease
    SYM2206 is a potent and non-competitive AMPA receptor antagonist, with an IC50 of 1.6 μM. SYM2206 blocks Nav1.6-mediated persistent currents .
    SYM2206
  • HY-105860
    Selurampanel

    BGG 492

    		 iGluR Neurological Disease
    Selurampanel (BGG 492) is an orally active and competitive AMPA receptor antagonist with an IC50 of 190 nM. Selurampanel has reasonable blood-brain barrier penetration. Selurampanel can be used for epilepsy research .
    Selurampanel
  • HY-15067
    DNQX
    5 Publications Verification

    FG 9041

    		 iGluR Cancer
    DNQX (FG 9041), a quinoxaline derivative, is a selective, potent competitive non-NMDA glutamate receptor antagonist (IC50s = 0.5, 2 and 40 μM for AMPA, kainate and NMDA receptors, respectively) .
    DNQX
  • HY-106467B
    Caroverine hydrochloride

    		iGluR Neurological Disease
    Caroverine hydrochloride is a potent, competitive and reversible antagonist of NMDA and AMPA glutamate receptor. Caroverine hydrochloride is also an antioxidant and calcium-blocking agent that exhibits vasorelaxant action. Caroverine hydrochloride can be used for the research of inner ear tinnitus .
    Caroverine hydrochloride
  • HY-103233
    DNQX disodium salt

    FG 9041 disodium salt

    		 iGluR Cancer
    DNQX (FG 9041) disodium salt, a quinoxaline derivative, is a selective, potent competitive non-NMDA glutamate receptor antagonist (IC50s = 0.5, 2 and 40 μM for AMPA, kainate and NMDA receptors, respectively) .
    DNQX disodium salt
  • HY-15066A
    CNQX disodium
    Maximum Cited Publications
    10 Publications Verification

    FG9065 disodium

    		 iGluR Neurological Disease
    CNQX disodium (FG9065 disodium) is a potent and competitive AMPA/kainate receptor antagonist with IC50s of 0.3 μM and 1.5 μM, respectively. CNQX disodium is a competitive non-NMDA receptor antagonist . CNQX disodium blocks the expression of fear-potentiated startle in rats .
    CNQX disodium
  • HY-15074
    SPD-502

    NS-1209

    		 iGluR Neurological Disease
    SPD-502 is a novel glutamate antagonist with potential neuroprotective properties, particularly in brain ischemia. It selectively targets the AMPA receptor, showing high affinity (IC50 = 0.043 μM) and competitive inhibition of AMPA-induced effects in rat cortical membranes and cultured mouse cortical neurons. In vivo, SPD-502 effectively blocks AMPA-evoked spike activity in the hippocampus after intravenous administration, significantly increasing the seizure threshold in mice and demonstrating robust protection against ischemia-induced damage to hippocampal neurons in gerbils. These findings suggest SPD-502 may be promising for treating neurodegenerative conditions associated with glutamate excitotoxicity .
    SPD-502
  • HY-15076
    SPD-502 sodium

    NS-1209 sodium

    		 iGluR Neurological Disease
    SPD-502 sodium is a novel glutamate antagonist with potential neuroprotective properties, particularly in brain ischemia. It selectively targets the AMPA receptor, showing high affinity (IC50 = 0.043 μM) and competitive inhibition of AMPA-induced effects in rat cortical membranes and cultured mouse cortical neurons. In vivo, SPD-502 sodium effectively blocks AMPA-evoked spike activity in the hippocampus after intravenous administration, significantly increasing the seizure threshold in mice and demonstrating robust protection against ischemia-induced damage to hippocampal neurons in gerbils. These findings suggest SPD-502 sodium may be promising for treating neurodegenerative conditions associated with glutamate excitotoxicity .
    SPD-502 sodium
  • HY-114379
    AS2717638
    1 Publications Verification

    		 LPL Receptor Inflammation/Immunology
    AS2717638 is an oral active and selective lysophosphatidic acid receptor 5 (LPA5) antagonist, with an IC50 of 38 nM for hLPA5. AS2717638 also significantly improves PGE2-, PGF2α-, and AMPA-induced allodynia .
    AS2717638
  • HY-15071
    YM90K

    		iGluR Neurological Disease
    YM90K is a potent and selective AMPA receptor antagonist with a Ki of 84 nM. YM90K is less potent in inhibiting kainate (Ki of 2.2 μM) and NMDA (Ki of 37 μM) receptors. YM90K has neuroprotective actions .
    YM90K
  • HY-15078
    NS1219

    (R)-SPD502

    		 iGluR Neurological Disease
    NS1219 ((R)-SPD502) is the isomer of NS 1209 HY-15074. NS1209 is a selective AMPA receptor antagonist with neuroprotective activity. NS1209 can be used for the research of stroke, neuropathic pain and epilepsy .
    NS1219
  • HY-107606
    UBP301

    		iGluR Neurological Disease
    UBP301 is a potent and selective antagonist of kainate receptor with IC50 and KD of 164 μM and 5.94 μM, respectively. UBP301 has ∼30-fold selectivity of kainate receptor over AMPA receptor. UBP301 is the derivative of willardiine .
    UBP301
  • HY-107606A
    UBP301 hydrochloride

    		iGluR Neurological Disease
    UBP301 hydrochloride is a potent and selective antagonist of kainate receptor with IC50 and KD of 164 μM and 5.94 μM, respectively. UBP301 hydrochloride has ～30-fold selectivity of kainate receptor over AMPA receptor. UBP301 hydrochloride is the derivative of willardiine .
    UBP301 hydrochloride
  • HY-107605
    UBP296

    		iGluR Neurological Disease
    UBP296 is a potent and selective antagonist of GLUK5-containing kainate receptor in the spinal cord. UBP296 reversibly blocks ATPA-induced depressions of synaptic transmission, and affects AMPA receptor-mediated synaptic transmission directly in rat hippocampal slices .
    UBP296
  • HY-121964
    cis-Piperidine-2,3-dicarboxylic acid

    		iGluR Neurological Disease
    Cis-piperidine-2,3-dicarboxylic acid is a non-specific antagonist of NMDA, AMPA and kainate ionotropic receptors and a partial agonist for NMDA receptors. Cis-piperidine-2,3-dicarboxylic acid can be used in blocking general excitatory synaptic transmissions .
    cis-Piperidine-2,3-dicarboxylic acid
  • HY-19435A
    GYKI-47261 dihydrochloride

    		iGluR Cytochrome P450 Neurological Disease
    GYKI-47261 dihydrochloride is a competitive, orally active, and selective AMPA receptor antagonist with an IC50 of 2.5 μM. GYKI-47261 has broad spectrum anticonvulsive activity and neuroprotective effects. GYKI-47261 dihydrochloride is also a potent inducer of CYP2E1 .
    GYKI-47261 dihydrochloride
  • HY-19435
    GYKI-47261

    		iGluR Cytochrome P450 Neurological Disease
    GYKI-47261 is a competitive, orally active, and selective AMPA receptor antagonist with an IC50 of 2.5 μM. GYKI-47261 has broad spectrum anticonvulsive activity and neuroprotective effects. GYKI-47261 is also a potent inducer of CYP2E1 .
    GYKI-47261
  • HY-103234A
    GYKI 52466 dihydrochloride

    		iGluR Neurological Disease
    GYKI 52466 dihydrochloride is an orally active, highly selective and noncompetitive AMPA/kainate receptor antagonist with the IC50 values of 7.5 and 11μM, respectively. GYKI 52466 dihydrochloride has good blood brain barrier permeability and anticonvulsant effect. GYKI 52466 dihydrochloride can be used in Parkinson's disease research .
    GYKI 52466 dihydrochloride
  • HY-103234
    GYKI 52466

    		iGluR Neurological Disease
    GYKI 52466 is an orally active, highly selective and noncompetitive AMPA/kainate receptor antagonist with the IC50 values of 7.5 and 11μM, respectively. GYKI 52466 has good blood brain barrier permeability and anticonvulsant effect. GYKI 52466 can be used in Parkinson's disease research .
    GYKI 52466
  • HY-103234B
    GYKI 52466 hydrochloride

    		iGluR Neurological Disease
    GYKI 52466 hydrochloride is an orally active, highly selective and noncompetitive AMPA/kainate receptor antagonist with the IC50 values of 7.5 and 11μM, respectively. GYKI 52466 hydrochloride has good blood brain barrier permeability and anticonvulsant effect. GYKI 52466 hydrochloride can be used in Parkinson's disease research .
    GYKI 52466 hydrochloride
  • HY-B0122
    Topiramate
    4 Publications Verification

    McN 4853; RWJ 17021

    		 iGluR GABA Receptor Sodium Channel Calcium Channel Potassium Channel Carbonic Anhydrase Neurological Disease
    Topiramate (McN 4853) is a broad-spectrum antiepileptic agent. Topiramate is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of kainate/AMPA receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase .
    Topiramate
  • HY-B0122A
    Topiramate lithium

    McN 4853 lithium; RWJ 17021 lithium

    		 iGluR GABA Receptor Sodium Channel Calcium Channel Potassium Channel Carbonic Anhydrase Neurological Disease
    Topiramate (McN 4853) lithium is a broad-spectrum antiepileptic agent. Topiramate lithium is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of kainate/AMPA receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase .
    Topiramate lithium
  • HY-19432
    UBP-282

    		iGluR Neurological Disease
    UBP-282 is a potent, selective and competitive AMPA and kainate receptor antagonist. UBP-282 inhibits the fast component of the dorsal root-evoked ventral root potential (fDR-VRP) with an IC50 value of 10.3 μM. UBP-282 antagonizes kainate-induced depolarisations of dorsal roots with a pA2 value of 4.96 .
    UBP-282

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: